Optimizing Therapies in Heart Failure: The Role of Potassium Binders

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Heart failure (HF) is a significant global health concern associated with reduced survival.
• Hyperkalemia (HK), affecting over 25% of HF patients in real-world settings, often impedes guideline-directed medical therapy (GDMT) intensification.
• HK in HF is frequently linked to pharmacological treatments, cardio-renal syndrome, and chronic kidney disease, worsening patient outcomes.

Purpose of the Study:

• To review the impact of novel potassium binders on heart failure management.
• To critically evaluate the daily application of sodium zirconium cyclosilicate (SZC) and patiromer for hyperkalemia in HF patients.
• To assess the efficacy and safety of new potassium binders in facilitating GDMT upgrades.

Main Methods:

• Narrative review of current literature on potassium binders in heart failure.
• Analysis of clinical trial data for sodium polystyrene sulfonate (SPS), sodium zirconium cyclosilicate (SZC), and patiromer.
• Evaluation of efficacy, safety, and long-term outcomes of novel potassium binders.

Main Results:

• SZC demonstrated rapid reduction of potassium levels within 48 hours and sustained normokalemia for up to 12 months.
• Patiromer achieved a statistically significant decrease in serum potassium for up to 52 weeks.
• Both SZC and patiromer exhibit a favorable side effect profile, supporting their clinical implementation.

Conclusions:

• Novel potassium binders, SZC and patiromer, are effective in managing chronic HK in HF patients.
• These agents facilitate the necessary up-titration of HF therapies, potentially improving patient prognosis.
• The favorable long-term results and safety profiles of SZC and patiromer support their integration into routine clinical practice for HF management.